Cleared Traditional

K213652 - Cresilon Hemostatic Gel, CHG, Cresilon Hemostatic Gel (CHG) (FDA 510(k) Clearance)

Jun 2023
Decision
586d
Days
-
Risk

K213652 is an FDA 510(k) clearance for the Cresilon Hemostatic Gel, CHG, Cresilon Hemostatic Gel (CHG). This device is classified as a Hemostatic Wound Dressing Without Thrombin Or Other Biologics.

Submitted by Cresilon, Inc. (Brooklyn, US). The FDA issued a Cleared decision on June 28, 2023, 586 days after receiving the submission on November 19, 2021.

This device falls under the General & Plastic Surgery FDA review panel. To Temporarily Control Bleeding And Cover External Wounds..

Submission Details

510(k) Number K213652 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 19, 2021
Decision Date June 28, 2023
Days to Decision 586 days
Submission Type Traditional
Review Panel General & Plastic Surgery (SU)
Summary Summary PDF

Device Classification

Product Code QSY - Hemostatic Wound Dressing Without Thrombin Or Other Biologics
Device Class -
Definition To Temporarily Control Bleeding And Cover External Wounds.